Massimo Guidoboni

6PUBLICATIONS
49CO-AUTHORS
Tumour immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 06, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

|Jan 03, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Paolo A Ascierto, Milena Casula, Jenny Bulgarelli

|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

Reinhard Dummer, Pippa Corrie, Ralf Gutzmer

|Sep 01, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci

|Jul 27, 2022
Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center.

Elena Pancisi, Anna Maria Granato, Emanuela Scarpi

|Nov 10, 2021
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).

Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava

Pageof 1

Frequent Collaborators

4 joint publications

Celeste Lebbè

4 joint publications

Paolo A Ascierto

3 joint publications

Vanna Chiarion-Sileni

3 joint publications

Reinhard Dummer